Novo Nordisk Foundation Cluster Lectures 2016 - Series 3
The Novo Nordisk Foundation Cluster Lectures are a series of open lectures for all researchers and other interested in and around the Copenhagen area. Every 4 weeks, on a Thursday evening, you are invited to Tuborg Havnevej for lectures on themes with a general interest for the Novo Nordisk Foundation Research Centers. Often there will be a cross-disciplinary focus. The third lecture on 17 March 2016 will feature 2 top level industry researchers explaining their recent research in diabetes and diabetes complications.
15:45 Welcome and registration (coffee/tea, fruit, water available)
16:00 Daniel Timmermann, Novo Nordisk
'Preventing and treating diabetes complications: A new commitment for Novo Nordisk'
16:45 Søren Østergaard, Novo Nordisk
'Peptide and protein engineering technologies in drug design'
17:30 Networking with a drink and a bite
18:30 Thank you for a splendid end of day!
Registration is free of charge, but mandatory on our event's website on Eventbrite
SAVE THE DATE
The next Cluster Lecture will take place on 14 April 2016. We look forward to meeting you there too! Do you have a good idea for a theme or inspiring speakers? Contact us at email@example.com
I would like to know more about upcoming Novo Nordisk Foundation Cluster Lectures - where can I find information?
You are very welcome to join the 'Novo Nordisk Foundation Research Centers' Linkedin group. There you will find information about upcoming lectures, and much more. Also, you may want to sign up for the weekly announcement with events and deadlines, sent out by the group manager.
What are my transport/parking options getting to the event?
You can park for free in front or at the side of Tuborg Havnevej 19. If that is full, there is 3 hours free parking in the parking to the Waterfront shopping mall at the end of the road.
Public transport by train to Hellerup station, and/or bus (1A, 21, 166), nearest by bus stop is Tuborg Boulevard.
How do I cancel my participation?
Please help us respecting our speakers, as well keeping track of the numbers and optimize lecture and catering to the audience by cancelling as soon as you know that you exceptionally will not be able to make it. You can either cancel through Eventbrite or send an email to Sophie Labrosse (firstname.lastname@example.org).
Where can I contact the organizer with any questions?
Contact Sophie Labrosse at email@example.com
A SHORT BIO OF THE SPEAKERS
Søren Østergaard received his Master of Science in Biochemistry in 1993 from University of Copenhagen and received his PhD in peptide and protein chemistry in 1997 working in the lab of Prof. Arne Holm (former Royal Vet. & Agr. University). In combination with his PhD he was working in the Dep. headed by Prof. Iver Heron at Statens Serum Institute (SSI) focusing on molecular mimicry of antibody-antigen recognition.
He then joined Novo Nordisk in 1997 in the Insulin Research area headed by Vice President Jan Markussen from which group the important insulins detemir (Levemir) and degludec (Tresiba) were developed. He has been working with identification of novel or improved peptide and nonpeptidic ligands through the use of combinatorial and peptide array technologies in many projects. During his work he has been working with many different protein and peptide targets varying from insulin mimetics, ligands for haemophilia proteins, epitope mapping of antibodies, array protease substrate analysis but notably design of efficacious peptide hormones. Within the last ten years he has been focusing on the design of peptide pharmaceuticals within the diabetes and obesity area, and also been a principal designer of the lipidation technology used across Novo Nordisk protein and peptide projects. He has led the design program of a PYY analogue currently in phase I for obesity and diabetes and in addition started new projects within the de novo design of new peptide pharmaceuticals. Recently Novo Nordisk has launched a talent ambassador program in which he together with other colleagues represent Global research on various career events.
He is also involved in collaboration with academia and currently has a post doc at Uppsala University in the group of Prof. Dan Larhammar within the area of molecular modelling using site directed mutagenesis, pharmacology and in silico ligand-receptor modelling. In addition he has a close collaboration with Prof. Kristian Strømgaard at the University of Copenhagen within the area of proteomics using array screening of peptide ligands.
Daniel B. Timmermann holds an MSc in Pharmacy and received a PhD in neurobiology in 2001. Bringing 12 years of drug discovery and managerial experience from the biotech/pharma sector, Daniel joined Novo Nordisk in 2013 where he is presently Corporate Vice President of Haemostasis & Vascular Pharmacology, an area encompassing drug discovery and research within haemophilia, growth disorders and diabetes complications.